Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe

Anne-Marie Miller, Mircea Balasa, Kaj Blennow, Mary Gardiner, Aleksandra Rutkowska, Philip Scheltens, Charlotte E. Teunissen, Pieter Jelle Visser, Bengt Winblad, Gunhild Waldemar, Brian Lawlor*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)201-210
Number of pages10
JournalJournal of Alzheimer's Disease
Volume60
Issue number1
DOIs
Publication statusPublished - 2017

Keywords

  • Alzheimer's disease
  • attitudes
  • biomarkers
  • cerebrospinal fluid
  • dementia
  • ALZHEIMERS ASSOCIATION WORKGROUPS
  • MILD COGNITIVE IMPAIRMENT
  • NINCDS-ADRDA CRITERIA
  • NATIONAL INSTITUTE
  • DISEASE DIAGNOSIS
  • CONSENSUS PAPER
  • CSF BIOMARKERS
  • STANDARDIZATION
  • RECOMMENDATIONS
  • GUIDELINES

Cite this

Miller, A-M., Balasa, M., Blennow, K., Gardiner, M., Rutkowska, A., Scheltens, P., Teunissen, C. E., Visser, P. J., Winblad, B., Waldemar, G., & Lawlor, B. (2017). Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease, 60(1), 201-210. https://doi.org/10.3233/JAD-170502